FindTrial
Sign In

A Randomized, Double-blind, Placebo-controlled Study on Treatment of Nocturia with Desmopressin in Women

A Randomized, Double-blind, Placebo-controlled Study on Treatment of Nocturia with Desmopressin in Women

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-09000690
Enrollment
Unknown
Registered
2006-10-14
Start date
2006-11-28
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nocturia

Interventions

Experimental:MINIRIN 0.2 mg tablets containing desmopressin acetate 0.2 mg and excipients q.s. (oral
1 dose per night for 3 weeks) Patients will experience 1-week screening period and 3-week double-blind period
Control:Placebo (oral
1 dose per night for 3 weeks)

Sponsors

N.A.
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: All female patients attending the Urodynamic Clinic at Prince of Wales Hospital and Queen Elizabeth Hospital with nocturia problems.

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

MeasureTime frame
Clinical efficacy of oral desmopressin in the treatment of nocturia in women and the effect of desmopressin on the study population with regards to quality of life and safety will be examinated and documented;—

Countries

China

Contacts

Public ContactDr. CHAN, Symphorosa Shing Chee
symphorosa@cuhk.edu.hk+852 2632 2814

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026